Indraprastha Medical Corporation posts consolidated Q2 FY26 PAT at Rs. 49.46 Cr

Indraprastha Medical Corporation has reported total income of Rs. 388.40 crore during the period ended September 30, 2025

MedPlus Health Services posts consolidated Q2 FY26 PAT at Rs. 55.50 Cr

Medplus Health Services has reported total income of Rs. 1,696.79 crore during the period ended September 30, 2025

Lilly’s Omvoh shows rapid and lasting relief from bowel urgency in ulcerative colitis patients

Novartis India posts Q2 FY26 PAT at Rs. 24.22 Cr

Novartis India has reported total income of Rs. 99.73 crore during the period ended September 30, 2025

Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome

Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva

Medherant announces positive Phase 1 results of clinical trial of testosterone patch for women

Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women

MIRA Pharmaceuticals advances oral Ketamir-2 into Phase 1 MAD study for chemotherapy-induced neuropathic pain

Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation

Dr Reddys Laboratories reports Q2 FY26 consolidated PAT at Rs. 1,437.2 Cr

Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025

CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors

The event will be attended by 35,000+ industry professionals

Laurus Labs posts Q2 FY26 consolidated PAT higher at Rs. 195 Cr

Laurus Labs has reported total income of Rs. 1,680.43 crore during the period ended September 30, 2025